| Literature DB >> 15450770 |
Naoki Kawaguchi1, Satoshi Kuwabara, Yuko Nemoto, Toshio Fukutake, Yoichi Satomura, Kimiyoshi Arimura, Mitsuhiro Osame, Takamichi Hattori.
Abstract
To clarify the current status of treatments and outcomes of patients with myasthenia gravis (MG) in Japan, a total of 470 patients (164 men and 306 women; mean age 41 years) were recruited from 19 Japanese tertiary medical centers in 1999-2000. Thymectomy was performed in 319 (68%) of the patients. Patients who received thymectomy were younger (p = 0.01) and had more severe disabilities (p < 0.01) than patients without thymectomy. Irrespective of receiving thymectomy, most of the patients were administered corticosteroids (64%), other immunosuppressive agents (10%), or cholinesterase inhibitors (86%). Of 395 patients followed up for more than 12 months after treatment (mean 8.0 years), 30% (34% of thymectomized and 21% of non-thymectomized patients) were in remission (no symptoms with/without medication), 34% had only ocular symptoms, and the remaining 35% still had weakness of bulbar or limb muscles at the end of follow-up. The prognosis of MG in Japan was generally favorable, but despite the frequent use of thymectomy and immunosuppressive treatments, approximately one-third of patients still had generalized weakness. More effective or intensive treatments are required to improve the prognosis.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15450770 DOI: 10.1016/j.jns.2003.09.016
Source DB: PubMed Journal: J Neurol Sci ISSN: 0022-510X Impact factor: 3.181